ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Trimmed by Virtus Investment Advisers Inc.

Virtus Investment Advisers Inc. cut its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 80.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,980 shares of the biotechnology company’s stock after selling 62,917 shares during the quarter. Virtus Investment Advisers Inc.’s holdings in ADMA Biologics were worth $257,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in ADMA Biologics by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company’s stock worth $312,109,000 after buying an additional 80,302 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of ADMA Biologics by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company’s stock worth $93,187,000 after acquiring an additional 50,399 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of ADMA Biologics by 16.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company’s stock worth $80,065,000 after acquiring an additional 643,661 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of ADMA Biologics by 2.8% during the fourth quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company’s stock worth $64,654,000 after purchasing an additional 102,692 shares during the period. Finally, Perpetual Ltd purchased a new stake in shares of ADMA Biologics during the fourth quarter valued at $62,300,000. 75.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently commented on ADMA shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th. StockNews.com downgraded ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Friday, May 9th. Finally, Raymond James upped their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, ADMA Biologics currently has a consensus rating of “Moderate Buy” and an average target price of $24.25.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $19.69 on Monday. The firm has a market capitalization of $4.70 billion, a PE ratio of 70.32 and a beta of 0.57. ADMA Biologics, Inc. has a 1-year low of $9.22 and a 1-year high of $25.67. The business’s 50 day moving average is $20.49 and its 200-day moving average is $18.86. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). The business had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. ADMA Biologics’s revenue was up 40.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.08 earnings per share. Sell-side analysts predict that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.